Results 61 to 70 of about 401,674 (278)

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Estimation of Key Comorbidities for Osteoarthritis Progression Based on the EMR-Claims Dataset

IEEE Access, 2019
Currently, some serious comorbidity-impacted chronic diseases have high incidence among older people in the U.S. Due to the incompleteness of the related clinical data, it is difficult to refine these diseases' staging and quantitatively assess risk ...
Wei Chen, Kun Wei, Weiling Zhao, Xiaobo Zhou   +3 more
doaj   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Competing risks analysis for neutrophil to lymphocyte ratio as a predictor of diabetic retinopathy incidence in the Scottish population

BMC Medicine, 2023
Background Diabetic retinopathy (DR) is a major sight-threatening microvascular complication in individuals with diabetes. Systemic inflammation combined with oxidative stress is thought to capture most of the complexities involved in the pathology of ...
Aravind Lathika Rajendrakumar, Simona M. Hapca, Anand Thakarakkattil Narayanan Nair, Yu Huang, Mehul Kumar Chourasia, Ryan Shun-Yuen Kwan, Charvi Nangia, Moneeza K. Siddiqui, Prathiba Vijayaraghavan, Shona Z. Matthew, Graham P. Leese, Viswanathan Mohan, Ewan R. Pearson, Alexander S. F. Doney, Colin N. A. Palmer   +14 more
doaj   +1 more source

Estimate hazard ratios in small clinical trials without reported hazard ratios

Discover Oncology
For survival studies, pooling hazard ratios (HRs) across multiple clinical trials through meta-analysis is commonly performed to achieve widely accepted and robust conclusions. However, clinical trials sometimes do not report HRs.We developed a new, simple approach to estimate HRs by reconstructing life tables from Kaplan-Meier (KM) curves ...
Shuyuan Wang, Ziwei Song, Mingjie Wu, Yuanjian Huang   +3 more
openaire   +3 more sources

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Subtleties in the interpretation of hazard ratios

, 2018
The hazard ratio is one of the most commonly reported measures of treatment effect in randomised trials, yet the source of much misinterpretation. This point was made clear by (Hernan, 2010) in commentary, which emphasised that the hazard ratio contrasts populations of treated and untreated individuals who survived a given period of time, populations ...
Martinussen, Torben, Vansteelandt, Stijn, Andersen, Per Kragh   +2 more
openaire   +2 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study

Emerging Microbes and Infections
Effectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak of SARS-CoV-2 omicron predominance in China has not been reported, yet.
Siyue Jia, Zundong Yin, Hongxing Pan, Fuzhen Wang, Xiaoqiang Liu, Qing Wang, Li Zhang, Jihai Tang, Hao Yang, Jiangbo Du, Zhiguo Wang, Pengfei Jin, Zhihang Peng, Rong Tang, Guodong Kang, Xuewen Wang, Simin Li, Weixiao Wang, Jingxin Li, Hongbing Shen, Fengcai Zhu   +20 more
doaj   +1 more source